Abstract：
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.
摘要：
欧洲妇科肿瘤学会，2022年6月15日至16日，欧洲肿瘤医学学会（ESMO）和欧洲病理学会在瓦伦西亚举行了关于卵巢癌的共识会议（CC），西班牙。CC小组包括44位卵巢癌和病理学管理专家，ESMO科学顾问和方法学家。目的是讨论新的或有争议的话题，并提出建议以改善和协调卵巢癌患者的管理。在四个主要主题下确定了18个问题供讨论：（i）病理学和分子生物学，（ii）妊娠早期疾病和盆腔肿块，（iii）晚期（包括老年/体弱患者）和（iv）复发性疾病。该小组分为四个工作组（WG），每个工作组都解决与上述四个主题之一有关的问题，基于他们的专业知识。相关科学文献已提前审查。工作组提出了建议，然后提交给整个小组进行进一步讨论和修改，然后再进行表决。这份手稿侧重于达成共识的建议声明，他们的投票结果和支持每一项建议的证据摘要。
